Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

News SummaryMost relevantAll newsSector newsTweets

Teva Pharmaceutical Industries : FDA approves a generic version of Teva Pharmaceutical's best-selling drug; company shares tumble

share with twitter share with LinkedIn share with facebook
share via e-mail
10/04/2017 | 07:26pm CET

Oct. 04--Teva Pharmaceutical Industries, grappling with a tough pricing environment for its generics business and planned layoffs of 7,000 employees worldwide, received a major blow Wednesday.

The Food and Drug Administration approved rival Mylan Labs' generic version of Teva's best-selling multiple sclerosis drug.

Teva is the world's largest maker of generic pharmaceuticals, but its branded medicine Copaxone is the company's best seller with global sales of $1.02 billion in the second quarter.

Mylan shares soared nearly 20 percent while Teva's stock fell more than 14 percent Wednesday morning.

"Lightning has struck," pharmaceutical analyst Ken Cacciatore of Cowen & Co. wrote in a client note. "Mylan has achieved what it had been unable to do over the last seven years, which was garner an approval for Copaxone."

Mylan said in a statement that shipping was imminent for its generic Glatiramer Acetate 40-milligram three times a week injection and its 20-milligram once injection.

Multiple sclerosis is a chronic disease of the central nervous system and affects an estimated 400,000 Americans.

The approvals "mark another significant milestone for our company," said Mylan CEO Heather Bresch in a news release, "and reinforces our proven capabilities in bringing complex and difficult to manufacture products to market."

Teva responded that "any launch by Mylan of a generic version of Copaxone 40-milligram prior to final resolution of the pending patent appeals and other patent litigation should be considered an 'at-risk' launch, which could subject Mylan to significant damages among other remedies."

Teva's interim president and CEO Yitzhak Peterburg said Teva has planned for the eventual introduction of a generic competitor.

"We remain confident in patient and physician loyalty to Teva's Copaxone due to its recognized efficacy, safety, and tolerability profile," he said, "and we will continue to promote and support the product." Teva said it was "too soon to officially comment on any change to our full-year business outlook."

Israel-based Teva's North America headquarters are in North Wales, Montgomery County. Teva employs more than 2,000 at five locations in Pennsylvania.

Mylan Labs is based in Canonsburg, Pa. The FDA said on Monday that it planned to introduce new measures to speed up bringing generic versions of complex drugs to market, as the government agency tries to deal with the rising cost of prescription medicines in the United States.

In a statement, Teva said it has two appeals that will be argued before a panel of judges on the U.S. Court of Appeals for the Federal Circuit. Teva said its early assessment of generic glatiramer acetate product launches is that its shares could be impacted "by at least 25 cents a share in the fourth quarter ending Dec. 31." Teva said it will provide additional details on its third-quarter earnings conference call on Nov. 2.

In a client note, Cacciatore said, "the approval of Mylan's 20 and 40- milligram Copaxone is the long-feared scenario that has now come true." At the same time, another drug maker Momenta/Sandoz is seeking approval of its 40 milligram generic version of Copaxone. "It will also eventually come, whether later next year or in early 2019," the analyst wrote.

Teva last month named a permanent CEO, Kare Schultz of Denmark's Lundbeck A/S, who was hired to engineer a turnaround as Teva grapples with a tough generic pricing environment.

Teva earlier announced a restructuring after Teva spent $40.5 billion in 2015 to buy out Allergan's generic business that has proven to be a drag on earnings.


(c)2017 Philly.com

Visit Philly.com at www.philly.com

Distributed by Tribune Content Agency, LLC.

© Tribune Content Agency, source Regional News

share with twitter share with LinkedIn share with facebook
share via e-mail
03/23TEVA PHARMACEUTICAL INDUSTRIES : Announces the Launch of a Generic Version of AL..
03/23Indivior loses another case in battle to protect opioid addiction drug
03/16TEVA PHARMACEUTICAL INDUSTRIES : scraps NTE integrated R&D project
03/15TEVA PHARMACEUTICAL INDUSTRIES : Announces Upsizing and Successful Pricing of $4..
03/15TEVA PHARMACEUTICAL INDUSTRIES : to Present at the Cowen & Company 38th Annual H..
03/15MANAGEMENT TRACKS : Cellectis, Five Prime
03/14TEVA PHARMACEUTICAL INDUSTRIES : scraps NTE integrated R&D project
03/14Drugmaker Hikma's FY profit, revenue meet expectations; shares rise
03/13TEVA PHARMACEUTICAL INDUSTRIES : patent exec joins law firm Eitan Mehulal & Sado..
03/13Teva rebuffs EU pay-for-delay charge at hearing
More news
News from SeekingAlpha
03/23Teva launches generic Aloxi in U.S. 
03/20JF'S CORE BIOTECH BUYS EDITION 1 VOL : Updates And Taking Advantage Of Current W.. 
03/19Trump to release opioid epidemic plan 
03/16Corcept sues Teva for infringing on Korlym patents 
03/15Desperate Allergan Seeks 'Sense Of Urgency' 
Financials ($)
Sales 2018 19 600 M
EBIT 2018 -
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 0,91x
Capi. / Sales 2019 0,91x
Capitalization 17 793 M
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 18,5 $
Spread / Average Target 6,2%
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani Executive Vice President-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Amir Elstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-6.11%351 935
PFIZER0.14%215 910
NOVARTIS-7.31%210 505
ROCHE HOLDING LTD.-12.21%198 996
MERCK AND COMPANY-3.82%147 455